Researchers at London Health Sciences Centre Research Institute (LHSCRI) have launched a Phase II clinical trial that aims to treat renal cell carcinoma (kidney cancer) by inserting microscopic beads filled with radiation directly into blood vessels surrounding cancerous tumours. The goal is to improve patient outcomes through a new treatment option.

Three graduate students in CSHL’s dos Santos lab have developed a tool called MaGNet to quickly measure changes in mouse mammary glands. This open-source technology can be used to study how hormonal changes affect mammary glands and may one day allow for earlier breast cancer diagnoses.

• Most patients receiving chemotherapy with taxanes or platinum salts develop painful neuropathy in hands and feet, often forcing dose reduction or treatment interruption.

• Published in Clinical and Translational Oncology, the study demonstrates that topical application of Oncapsisens® delays and reduces neuropathic symptoms, paving the way for new preventive options for cancer patients.

Researchers at Integra Therapeutics, in collaboration with the Pompeu Fabra University (UPF) Department of Medicine and Life Sciences (MELIS) and the Center for Genomic Regulation (CRG), have designed and experimentally validated new synthetic proteins that can edit the human genome more efficiently than proteins provided by nature. This work, a global pioneer published today in the journal Nature Biotechnology, will be of great use in improving the current gene editing tools used in biotechnology research and personalized medicine by developing cellular (CAR-T) and gene therapies, especially to treat cancer and rare diseases.